News >

BTK Combos Potentially Poised to Be New Standard MCL Treatment

Nichole Tucker
Published: Wednesday, Oct 09, 2019

Simon Rule, MD, PhD, a professor of hematology at Plymouth University Medical School

Simon Rule, MD, PhD

Looking forward to future therapeutic approaches in the frontline setting of mantle cell lymphoma (MCL), Simon Rule, MD, explained that BTK inhibitors could take over the upfront space and potentially in combination, adding that chemotherapy will be a subsequent option. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x